Pentoxifylline and Gliclazide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pentoxifylline (pentoxifylline) and Gliclazide (gliclazide). Common drug interactions include fall among females and anaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Pentoxifylline and Gliclazide. It is created by eHealthMe based on reports of 45 people who take the same drugs from the FDA, and is updated regularly.

What is Pentoxifylline?

Pentoxifylline has active ingredients of pentoxifylline. eHealthMe is studying from 5,997 Pentoxifylline users. Check the latest studies of Pentoxifylline.

What is Gliclazide?

Gliclazide has active ingredients of gliclazide. It is often used in diabetes. eHealthMe is studying from 28,131 Gliclazide users. Check the latest studies of Gliclazide.



On Jul, 25, 2026

45 people who take Pentoxifylline and Gliclazide together, and have interactions are studied.

Pentoxifylline and Gliclazide drug interactions.

What are the common drug interactions of Pentoxifylline and Gliclazide, by gender? *:

female:

  1. Fall
  2. Femoral neck fracture (neck of femur bone fracture)
  3. Paraplegia (paralysis of the legs and lower body)
  4. Spinal epidural haematoma (blood clot into the epidural space in the spine)
  5. Extradural haematoma (traumatic brain injury-collection of blood in the 'potential' space between the skull and the outer protective)
  6. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  7. Diarrhoea
  8. Endometrial cancer
  9. Blood glucose decreased
  10. Blood glucose fluctuation

male:

  1. Anaemia (lack of blood)
  2. Facial paralysis (loss of function of face muscle)
  3. Pneumonia
  4. Pyothorax (accumulation of pus in the pleural cavity)
  5. Angina pectoris (chest pain due to ischemia of the heart muscle)
  6. Asthenia (weakness)
  7. Blood creatinine increased
  8. Body temperature increased
  9. Bone pain
  10. Bradycardia (abnormally slow heart action)

What are the common drug interactions of Pentoxifylline and Gliclazide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Facial paralysis (loss of function of face muscle)
  2. Helicobacter infection (helicobacter pylori (h. pylori) infects stomach)
  3. Oesophagitis (inflammation of oesophagus)
  4. Angina pectoris (chest pain due to ischemia of the heart muscle)
  5. Asthenia (weakness)
  6. Bone pain
  7. Decreased appetite
  8. Dyslipidaemia (abnormal amount of lipids)
  9. Eye pain
  10. Gout (uric acid crystals building up in the body)

50-59:

  1. Anaemia (lack of blood)
  2. Carotid artery stenosis (narrowing of carotid artery)
  3. Cerebral ischaemia (insufficient blood flow to the brain to meet metabolic demand)
  4. Pneumonia
  5. Pyothorax (accumulation of pus in the pleural cavity)
  6. Body temperature increased
  7. Cough
  8. Disease progression
  9. Neuropathy (damage to nerves)
  10. Non-small cell lung cancer (type of epithelial lung cancer)

60+:

  1. Fall
  2. Femoral neck fracture (neck of femur bone fracture)
  3. Diarrhoea
  4. Endometrial cancer
  5. Hyperkalaemia (damage to or disease of the kidney)
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Blood creatinine increased
  8. Blood glucose decreased
  9. Blood glucose fluctuation
  10. Blood glucose increased

What are the existing conditions these people have? *

  1. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 16 people, 35.56%
  2. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 16 people, 35.56%
  3. High Blood Pressure: 13 people, 28.89%
  4. Type 2 Diabetes: 10 people, 22.22%
  5. Peripheral Vascular Disorder: 9 people, 20.00%
  6. Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 7 people, 15.56%
  7. Hyperlipidaemia (presence of excess lipids in the blood): 6 people, 13.33%
  8. Cardiac Disorder: 5 people, 11.11%
  9. Headache (pain in head): 4 people, 8.89%
  10. Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 4 people, 8.89%

* Approximation only. Some reports may have incomplete information.

Do you take Pentoxifylline and Gliclazide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Pentoxifylline and Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Pentoxifylline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Gliclazide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentoxifylline and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Gliclazide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on pentoxifylline and gliclazide (the active ingredients of Pentoxifylline and Gliclazide, respectively), and Pentoxifylline and Gliclazide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: